1. Home
  2. MBOT vs CRDL Comparison

MBOT vs CRDL Comparison

Compare MBOT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Microbot Medical Inc.

MBOT

Microbot Medical Inc.

HOLD

Current Price

$2.34

Market Cap

166.6M

Sector

Health Care

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.49

Market Cap

154.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBOT
CRDL
Founded
2010
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.6M
154.1M
IPO Year
2000
2017

Fundamental Metrics

Financial Performance
Metric
MBOT
CRDL
Price
$2.34
$1.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$7.50
$8.67
AVG Volume (30 Days)
1.4M
1.0M
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
60.27
N/A
EPS
N/A
N/A
Revenue
$116,887.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$119.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$0.88
52 Week High
$4.62
$1.59

Technical Indicators

Market Signals
Indicator
MBOT
CRDL
Relative Strength Index (RSI) 45.66 69.76
Support Level $1.99 $0.95
Resistance Level $2.67 $1.59
Average True Range (ATR) 0.15 0.10
MACD -0.02 0.01
Stochastic Oscillator 22.28 95.74

Price Performance

Historical Comparison
MBOT
CRDL

About MBOT Microbot Medical Inc.

Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: